Drug intelligence / Profile preview

Lubazodone

Development stage: Discontinued
Lead developer: Mitsubishi Tanabe Pharma
Modality: Small Molecules
Administration: Oral

Overview

Lubazodone is an investigational antidepressant that belongs to the class of serotonin receptor antagonists and reuptake inhibitors (SARIs). It was developed as a potential treatment for major depressive disorder. Lubazodone acts primarily by inhibiting the reuptake of serotonin and antagonizing specific serotonin receptors, notably serotonin 5-HT2A receptor. Its mechanism is similar to that of trazodone but with a different pharmacological profile intended to improve tolerability and efficacy. Lubazodone was developed by Mitsubishi Tanabe Pharma.

Targets

HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on Lubazodone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lubazodone.

Explore the full profile